# Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

> **NCT01030640** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 28 (actual)

## Conditions studied

- Osteoarthritis Pain
- Chronic Low Back Pain
- Pain Due to Interstitial Cystitis

## Interventions

- **OTHER:** placebo
- **BIOLOGICAL:** tanezumab

## Key facts

- **NCT ID:** NCT01030640
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030640, "Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01030640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*